NCT06663202

Brief Summary

The primary aim of the study is to evaluate the efficacy of either fibre retention osseous resective surgery (FibReORS) or conservative surgery with or without PPT in the treatment of deep residual pockets ≥ 6 mm in stage III-IV periodontitis patients after cause related therapy (step II) in terms of endpoints of therapy and other secondary outcomes at different time intervals (1, 3 and 5 years). Moreover, the study aims to evaluate the stability of the results obtained for the different surgical approaches over a 5 years follow-up period.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
44mo left

Started Nov 2024

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Nov 2024Jan 2030

First Submitted

Initial submission to the registry

October 22, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 29, 2024

Completed
17 days until next milestone

Study Start

First participant enrolled

November 15, 2024

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

October 31, 2024

Status Verified

October 1, 2024

Enrollment Period

5.1 years

First QC Date

October 22, 2024

Last Update Submit

October 28, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pocket closure

    Defined as probing pocket depth (PPD) of 3 mm or less or PPD of 4 mm with the absence of Bleeding on Probing in sites with PPD equal or more than 6 mm at baseline.

    5 years

Secondary Outcomes (5)

  • Mean Probing Pocket Depth changes

    5 Years

  • Mean Clinical Attachment Level changes

    5 years

  • Mean recession changes

    5 years

  • Tooth Retention

    5 years

  • Number of instrumentation re-intervention

    5 years

Other Outcomes (2)

  • Pain after surgery

    14 days

  • Discomfort during surgery

    Immediately after surgery.

Study Arms (3)

Fiber Retention Osseous Resective Surgery

EXPERIMENTAL

Paramarginal incisions both on buccal and lingual/palatal sides with bone remodelling preserving the supracrestal fibers

Procedure: Fiber retention osseous resective surgery

Papilla preservation flap

ACTIVE COMPARATOR

Access flap for open flap debridement using intrasulcular incisions and papilla preservation approaches to preserve the entire interdental tissues

Procedure: Papilla preservation flap

Conventional surgery

ACTIVE COMPARATOR

Access flap for open flap debridement using a conventional modified Widman flap procedure

Procedure: Widman flap procedure

Interventions

At the buccal and lingual sides, paramarginal or intrasulcular incisions will be made based on probing pocket depth values and the width of keratinised tissues. Thinned palatal flap technique will be performed on the palatal side. Bone remodelling will be carefully made using manual or rotary instruments in order to reshape positive attached fibres/bony architecture utilising the FibReORS technique, great attention will be made to distinguish between inflammatory granulation tissue and connective tissue fibres attached to root cementum by means of periodontal probe. Flaps will be positioned at the level of the alveolar crest without tension.

Fiber Retention Osseous Resective Surgery

Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used. Suturing will be performed with external vertical mattress sutures to achieve primary intention closure.

Papilla preservation flap

Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures.

Conventional surgery

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of stage III/IV periodontitis.
  • Completed steps I-II periodontal therapy at least 6 weeks before.
  • Full Mouth Plaque Score less than 15% at re-evaluation.
  • Full Mouth Bleeding Score less than 15% at re-evaluation.
  • Posterior sextant with residual PPD ≥ 6 mm at ≥ 2 natural teeth (third molars excluded).
  • Signed informed consent.

You may not qualify if:

  • Compromised general health which contraindicates the study procedures (ASA III-VI patients).
  • Systemic diseases/medications which could influence the outcome of the therapy (e.g. uncontrolled diabetes mellitus, non-plaque-induced gingival diseases, antiepileptic drugs (phenytoin and sodium valproate), certain calcium channel-blocking drugs (e.g., nifedipine, verapamil, diltiazem, amlodipine, felodipine), immunoregulating drugs (e.g., ciclosporine), and high-dose oral contraceptives).
  • Pregnant or nursing women.
  • Presence of tooth mobility ≥ class 2.
  • Presence of furcation involvement ≥ II degree (Hamp 1975) at the affected teeth.
  • Presence of deep infrabony defects (≥ 3 mm) at the involved sextant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Periodontitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Central Study Contacts

Mario Aimetti, Prof.

CONTACT

Giacomo Baima

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 22, 2024

First Posted

October 29, 2024

Study Start

November 15, 2024

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Last Updated

October 31, 2024

Record last verified: 2024-10